Invezz
09 Jul 2026, 08:49 UTC · 17w ago
AstraZeneca shares plunge as Wainua fails late-stage heart disease trial
Impact · against what's priced in
AstraZeneca faces a significant valuation hit as the failure of the Wainua trial removes a primary multi-billion-dollar growth driver. Ionis Pharmaceuticals experiences a more moderate decline, as the failure is specific to one program rather than a collapse of its core antisense technology platform.
- AZN−0.80
No priced-in read yet
- In context
The failure of the Wainua late-stage trial to reduce cardiovascular deaths removes a key multi-billion-dollar growth driver, triggering a nearly 10% share price drop.
Read from the article alone
Search tags
